Tamoxifenum

E Vicipaedia
Jump to navigation Jump to search
Esculaap4.svg
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.


Tamoxifenum
Tamoxifenum
Tamoxifenum
Natura chemica
Formula chemica C26H29NO
Massa molaris 371.515 g/mol
PubChem 2733526
DrugBank DB00675
Natura pharmacologica
Codex ATC L02BA01 (WHO)
Tempus semivitae biologicum 5-7 dies
Metabolismus iecore (hepaticus)
Metabolitus Afimoxifenum, Endoxifenum
Substratum enzymi CYP2C9
CYP2D6
CYP3A4
Excretio faecibus 65%, renibus 9%
Ad usum therapeuticum
Applicatio per os
MedlinePlus a682414 (Anglice)

Tamoxifenum est prodroga, at metaboliti activi eius, Afimoxifenum et Endoxifenum potissime receptoriis oestrogenii adiungunt. Usus est therapia et complementum cancri mammae[1].

Tamoxifenum in ordinis mundi sanitarii indicem exemplarem medicamentorum principalium receptum est.

Natura Tamoxifeni[recensere | fontem recensere]

Natura chemica[recensere | fontem recensere]

Nomen IUPAC suum est (Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethyl-aethylaminum. Formula chemica summa Ciprofloxacini est C26H29NO , massa molaris sua 371.515 g/mol.

Natura pharmacologica[recensere | fontem recensere]

Tamoxifenum est aromatasis inhibitor. Substantia in codice ATC reperitur: L02BA01 (WHO).

Effectus Tamoxifeni[recensere | fontem recensere]

Effectus non grati[recensere | fontem recensere]

Cum Tamoxifeni consumptione effectus secundarios et interactiones observati sunt, per exemplo:

Nexus interni

Notae[recensere | fontem recensere]

  1. Criscitiello C, Fumagalli D, Saini KS, Loi S (2010). "Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection". Onco Targets Ther 4: 1-11 
  2. Paganini-Hill A, Clark LJ (2000). "Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen". Breast Cancer Res Treat 64 (2): 165-76 

Nexus externi[recensere | fontem recensere]